The combination of rapid growth, individual product and process complexity, and limited industry-specific guidance or awareness presents ongoing challenges for transitioning from development to clinical and commercial manufacturing scale. For allogeneic therapies, having access to consistent and reliable donors and high quality, GMP-compliant starting material, coupled with the ability to consistently deliver this clinical source material to the required point of use, will be key to long-term success.
To watch this webinar, click here
Three diverse stakeholders share their experience and insights to help you troubleshoot your own cell therapy raw and starting materials strategy:
- Christopher Good (Biocair) highlights regional and regulatory logistics requirements, and the major considerations for shipping clinical/GMP starting materials
- Dominic Clarke (HemaCare) introduces the key considerations for starting material sourcing, including addressing translational and scale-up challenges.
- Amy Shaw (Beam Therapeutics) provides practical guidance relating to the critical role of both material sourcing and logistics in the effective development of novel advanced therapies, drawing on Beam’s own experiences with the development of its autologous and allogeneic product candidates.
Watch this webinar and improve your knowledge of:
- The importance of defining source material requirements for translation of allogeneic advanced therapies
- The benefits of a reliable & recallable donor network for consistent source material access
- The critical requirements for obtaining GMP-compliant source materials necessary for commercial manufacture
- How to navigate the critical aspects in handling, monitoring, and delivering temperature sensitive source materials
- The importance of early planning, coordination, and communication with all stakeholders